Effect of statins on platelet function in patients with hyperlipidemia

Archives of Medical Science

Volumn 9, Issue 4, 2013, Pages 622-628

  Sikora, Joanna ^a   Kostka, Barbara ^a   Marczyk, Iwona ^a   Krajewska, Urszula ^a   Chałubiński, Maciej ^a   Broncel, Marlena ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Hyperlipidemia; Platelet adhesion; Platelet aggregation; Statins

Indexed keywords

ADENOSINE DIPHOSPHATE; ATORVASTATIN; COLLAGEN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; RISTOCETIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84883348098     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2013.36905     Document Type: Article

References (35)

1. Kamath S, Blann AD, Lip GYH. Platelet activation: Assessment and quantification. Eur Heart J 2001; 22: 1561-71.
2. Hartwich J, Dembińska-Kieć, Gruca A, et al. Regulation of platelet adhesion by oxidized lipoproteins and oxidized phospholipids. Platelets 2002; 13: 141-51.
3. Cha YJ, Chang EA, Kim C. Effects of endothelial cells and mononuclear leukocytes on platelet aggregation. Haematologia 2000; 30: 97-106.
4. Gaddam V, Li DY, Metha JL. Anti-thrombotic effects of atorvastatin-an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Therapeut 2002; 7: 247-53.
5. van Willigen G, Gorter G, Akkerman JW. LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb 1994; 14: 41-6.
6. Hackeng CM, Huigsloot M, Pladet MW, Nieuwenhuis HK, van Rijn HJM, Akkerman JWN. Low-density lipoprotein enhances platelet secretion via integrin-alphaIIbbeta3- mediated signaling. Arterioscler Thromb Vasc Biol 1999; 19: 239-47.
7. Vlasova II. The effect of oxidatively modified low-density lipoproteins on platelet aggregability and membrane fluidity. Platelets 2000; 11: 406-14.
8. Chalubinski M, Broncel M. The influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in the treatment of autoimmune disorders. Med Sci Monit 2010; 16: 11.
9. Takemoto M, Liao JK. Pleiotropic effects of 3-hydro xy- 3-methylglutaryl coenzyme A reductase inhibitors. Atheroscler Thromb Vasc Biol 2001; 21: 1712-9.
10. Maurer-Spurej E, Pfeiler G, Maurer N, Lindner H, Glatter O, Devine DV. Room temperature activates human blood platelets. Lab Invest 2001; 8: 581-92.
11. Walkowiak B, Michalak E, Koziołkiewicz W, Cierniewski CS. Rapid photometric method for estimation of platelet count in blood plasma in platelet suspension. Thromb Res 1989; 56: 763-6.
12. Born GV. Aggregation of blood platelets by adenosine and reversal. Nature 1962; 195: 927-9.
13. Kostka B, Pajak W. The aggregometer equipment for recording of transmittance (T) with the possibility of scale extension. Diagn Lab 1985; 21: 43-7.
14. Kostka B, Sikora J, Para J, Krajewska U, Korzycka L. A new nitrate derivative of piperazine: Its influence on platelet activity. Blood Coagul Fibrinol 2007; 18: 151-6.
15. Sikora J, Krajewska U, Gietka M, Kostka B. The application of pig blood in the in vitro measurement of platelet adhesion. Pharmazie 2001; 56: 187-8.
16. Bellavite P, Andrioli G, Guzzo P, et al. A colorimetric method for the measurement of platelet adhesion in plates. Anal Biochem 1994; 216: 444-50.
17. Clauss A. Rapid physiological coagulation method for the determination of fibrinogen. Acta Haemat 1957; 17: 237.
18. Balk EM, Lau J, Gaudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease. Ann Intern Med 2003; 139: 670-82.
19. Veselka J, Hájek P, Malý, et al. Predictors of coronary intervention-related myocardial infarction in stable angina patients pre-treated with statins. Arch Med Sci 2011; 7: 67-72.
20. Xu M, Yuan G, Wei F. Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials Arch Med Sci 2010; 6: 866-73.
21. Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet 2010; 376: 1916-22.
22. Puccetti L, Pasqui AL, Auteri A, Bruni F. Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 121-6.
23. Piotrowski M, Fisher S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose Atorvastatin compared with higher-dose Atorvastatin alone. J Am Coll Cardiol 2007; 49: 1035-42.
24. Puccetti L, Pasqui AL, Pastorelli M, et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003; 90: 476-82.
25. Tziomalos K, Athyros VG, Mikhailidis DP. Statin dis continuation: An underestimated risk? Curr Med Res Opin 2008; 24: 3059-62.
26. Jagroop IA, Persaud JW, Mikhailidis DP. A new rapid method to measure human platelet cholesterol: A pilot dtudy. Clin Appl Thromb Hemost 2011; 17: 578-84.
27. Puccetti L, Pasqui AL, Pastorelli M, et al. Time-dependent effect of statins on platelet function in hypercho lesterolaemia. Eur J Clin Invest 2002; 32: 901-8.
28. Bolaman Z, Kadikoylu G, Ozgel N, Yenisey C. Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia. J Natl Med Assoc 2006; 98: 1273-7.
29. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia: A pilot study involving serial sampling. Curr Med Res Opin 2001; 16: 269-75.
30. Bonnefoy A, Liu Q, Legrand, Frojmovic MM. Efficiency of platelet adhesion to fibrinogen depends on both cell activation and flow. Biophysical J 2000; 78: 2834-43.
31. Ozaki Y. Measurement of platelet aggregation and attempts for standardization. Sysmex J Inter 1998; 8: 15-22.
32. Hussain O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercho lesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 2008; 65: 637-45.
33. Dujove CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol 2000; 85: 350-3.
34. Dai K, Bodnar R, Berndt MC, Du X. A critical role for 14-3- 3zeta protein in regulating the VWF binding function of platelet glycoprotein Ib-IX and its therapeutic implications. Blood 2005; 106: 1975-81.
35. Szapary L, Horvayh B, Marton Z, et al. Short-term effects of low-dose Atorvastatin on haemorrheological pa rameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs 2004; 18: 165-72.